BillionToOne Q2 revenue rises 64% as test volumes grow

BillionToOne

05/08/2026 21:39

Overview
Molecular diagnostics firm's Q2 revenue rose 64% yr/yr, driven by higher test volumes and ASP
Company posted Q2 net income of $8.1 mln, reversing prior-year loss
Full-year revenue guidance reiterated at $450-465 mln, with profitability expected to continue

Outlook
BillionToOne reiterates 2026 revenue guidance of $450 mln to $465 mln
Company expects to maintain profitability similar to current levels in 2026

Result Drivers
TEST VOLUME GROWTH - Co said 35% increase in tests delivered drove higher Q2 revenue
HIGHER AVERAGE SELLING PRICE - 21% yr/yr rise in ASP contributed to revenue and margin gains
ONCOLOGY SEGMENT EXPANSION - Oncology clinical testing revenue rose 176%, though higher costs per test offset some margin gains

Company press release: ID:nGNX7f0lgy

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$109.40 mln
 
Q2 EPS
 
$0.15
 
Q2 Net Income
 
$8.10 mln
 
Q2 Income from Operations
 
$5.50 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for BillionToOne, Inc. is $120.00, about 15.6% below its August 4 closing price of $142.25

Reuters Recommended Reads
Aug 4 - Revvity Q2 revenue beats estimates on diagnostics growth
Aug 4 - Bio-Rad Q2 revenue beats analyst estimates on clinical diagnostics growth
Aug 4 - Switzerland's SOPHiA GENETICS Q2 revenue rises on Liquid Biopsy growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)